Managing ovarian cancer in the PARP inhibitor era
The role of PARP inhibitors features in a number of sessions at the ESMO Gynaecological Cancers Congress 2022
KEYNOTE-826 trial met its dual primary endpoints
Survival benefit with first-line pembrolizumab plus chemotherapy in persistent, recurrent or metastatic cervical cancer
PARP inhibitor re-treatment: the future of maintenance therapy for relapsed ovarian cancer?
A significant progression-free survival improvement after re-treatment with olaparib was reported in the OReO/ENGOT Ov-38 trial
Prevention and early detection are pivotal in LMICs, but not enough
While locally tailored cancer screening programmes, particularly for cervical cancer, are showing encouraging results in some areas with limited resources, cancer care is still suffering some bottlenecks due to lack of training for healthcare staff and shortages of medicines
PARP inhibitors expand their role beyond BRCA mutations in first-line, newly diagnosed ovarian cancer
Favourable results were presented from three phase III trials which are likely to lead to a practice-changing role for PARP inhibitors in the treatment of newly diagnosed advanced ovarian cancer
Cediranib–olaparib combination is effective regardless of disease mutations
Results from the BAROCCO trial may help define the optimum treatment schedule for an antiangiogenic–PARP inhibitor combination in recurrent, platinum-resistant ovarian cancer